Structural Based Drug Discovery: The Significance of Protein Structure

Structural-based drug discovery is becoming the essential tool for drug development withlower cost and higher efficiency compared to the conventional method. Knowledge of the three-dimensional structure of protein targets has the potential to accelerate the process for screening drug candidates. X-ray crystallography has proven to be the most used and indispensable technology in structural-based drug discovery. The provided comprehensive structural information about the interaction between the disease-related protein target and ligand can guide the chemical modification on the ligand to improve potency and selectivity. X-ray crystallography has been upgraded from traditional synchrotron to the third generation, which enabled the surge of the structural determination of macromolecular. The introduction of X-ray free electron laser further alleviated the uncertain and time-consuming crystal size optimization process and extenuated the radiation damage by “diffraction before destruction”. EV-D68 2A protease was proved to be an important pharmaceutical target for acute flaccid myelitis. This thesis reports the first atomic structure of the EV-D68 2A protease and the structuresof its two mutants, revealing it adopting N-terminal four-stranded sheets and C-terminal six-stranded ß-barrels structure, with a tightly bound zinc atom. These structures will guide the chemical modification on its inhibitor, Telaprevir. Integrin ⍺Mβ2 is an integrin with the α I-domain, related to many immunological functions including cell extravasation, phagocytosis, and immune synapse formation, so studying the molecular ligand-binding mechanism and activation mechanism of ⍺Mβ2 is of importance. This thesis uncovers the preliminary crystallization condition of ⍺Mβ2-I domain in complex with its ligand Pleiotrophin and the initial structural model. The structural model shows consistency with the previous hypothesis that the primary binding sites are metal iondependent adhesion sites on ⍺Mβ2-I domain and the thrombospondin type-1 repeat (TSR) domains of Pleiotrophin. Drug molecules with high potency and selectivity can be designed based on the reported structures of the EV-D68 2A protease and ⍺Mβ2-I domain in the future.